| ProductType | PolyclonalAntibody |
| Units | 1ml |
| Host | Rabbit |
| Speciesreactivity | BroadHuman |
| Application | ELISAIHCnotestablished |
BackgroundThisantibodyissuitableforthedetectionofdifferentAGEproductsintissues,tissueextractsandbodyfluids.Long-termincubationofproteinswithglucoseleads,throughSchiff"sbaseandAmadorirearrangementproducts,totheformationofadvancedglycationendproducts(AGE)whicharecharacterizedbyfluorescence,browncolorandinter-andintra-molecularcross-linking.Recentimmunologicalstudiesusinganti-AGEantibodiesdemonstratedthepresenceofAGEin(i)humanlens,(ii)renalproximaltubulesinpatientswithdiabeticnephropathyandchronicrenalfailure,(iii)atheroscleroticlesionsofarterialwalls,(iv)ß2-microglobulinofcarpaltunnelamyloidfibrildepositsinpatientswithhemodialysis-relatedamyloidosisand(v)braintissuesofpatientswithAlzheimer’sdisease.TheseresultssuggestedthepotentialroleofAGEinnormalagingandage-enhanceddiseaseprocesses.AdvancedGlycationEndProducts(AGE),cross-reactivityBSAandHSA<1%.>
SourceSerumfromrabbitsimmunizedwithAdvancedGlycationEndProducts/BSA/HSA
Immunogen:AdvancedGlycationEndProducts/BSA/HSA
ProductProteinAaffinitypurifiedIgGinPBS0.05M;pH7.15;0.85%NaCl;0.05%sodiumazide**
PurificationMethod:ProteinAaffinitypurifiedIgGinPBSpH7.15containg0.05%sodiumazide**
Concentration:Approximately1mg/ml
SecondaryReagents:WerecommendtheuseofBIOLOGO"sUniversalStainingSystemDAB(Art.No.DA005)orAEC(Art.No.AE005).
Specificity
SpeciesReactivity:Human
ApplicationsELISA,IHCnotestablished
IncubationTime:60minatRTor18hrat2-8°C
WorkingConcentration:(liquidconc.)ELISAapp.1µg/ml,(IHC5-10µg/ml)
PositiveControl:humanlens,arterioscleroticplaques
Storage-20°C
CautionThisproductisintendedFORRESEARCHUSEONLY,andFORTESTSINVITRO,notforuseindiagnosticortherapeuticproceduresinvolvinghumansoranimals.Itmaycontainhazardousingredients. PleaserefertotheSafetyDataSheets(SDS)foradditionalinformationandproperhandlingprocedures.Disposeproductremaindersaccordingtolocalregulations.Thisdatasheetisasaccurateasreasonablyachievable,butExalphaBiologicalsacceptsnoliABIlityforanyinaccuraciesoromissionsinthisinformation.
References1.HoriuchiS.,ArakiN.,andMorinoY.(1991)ImmunologicalapproachtocharacterizeadvancedglycationendproductsoftheMaillardreaction:Evidenceforthepresenceofacommonstucture.J.Biol.Chem.266;7329-7332.2.ArakiN.,UenoN.,ChakrabartiB.,MorinoY.,andHoriuchiS.(1992)Immunochemicalevidenceofthepresenceofadvancedglycationendproductsinhumanlensproteinsanditspositivecorrelationwithaging.J.Biol.Chem.267;10211-10214.3.MiyataT.,OdoO.,InagiR.,IidaY.,ArakiN.,YamadaN.,HoriuchiS.,TaniguchiN.,Maeda,etal.(1993)ß2-Microglobulinmodifiedwithadvancedglycationendproductsisamajorcomponentofhaemodialysis-associatedamyloidosis.J.Clin.Invest.92;1243-1252.4.KumeS.,TakeyaM.,MoriT.,ArakiN.,SuzukiH.,HoriuchiS.,KodamaT.,MiyauchiY.,andTakahashiK.(1995)Immunohistochemicalandultrastructuraldetectionofadvancedglycationendproductsinatheroscleroticlesionsofhumanaortausinganovelspecificmonoclonalantibody.AmJ.Pathol.147;654-667.5.KimuraT.,TakamatsuJ.,IkedaK.,KondoA.,MiyakawaT.,andHoriuchiS.(1996)AccumulationofadvancedglycationendproductsoftheMaillardreactionwithageinhumanhippocampalneurons.Neurosci.Lett.208;53-56.
SafetyDatasheet(s)forthisproduct:EA_SodiumAzide/wp-content/uploads/SDS/AntibodySDSwithSodiumAzideV2.pdf
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
说得简单点就是，细胞核是原封不动的，没有重组过，而细胞核外的东西是很多别的细胞中提取出来的并组合起来的。这样的混合体淋巴细胞产生的抗体具有很强的嵌合能力，针对性比一般的抗体强，但是它的来源没变，所以称之为混合单克隆抗体
制备抗体都需要进行纯化处理
清冷冻干燥后保存。
没有marker，怎么知道你做的蛋白大小？
没有参照物，怎么知道你跑的快不快？
没有尺子，怎么知道你的size大小？
凭嘴说吗？
单克隆抗体这项新技术从根本上解决了在抗体制备中长期存在的特异性和可重复性问题，可用于探讨: ①蛋白质的精细结构；②淋巴细胞亚群的表面新抗原；③组织相容性抗原；④激素和药物的放射免疫（或酶免疫）分析；⑤肿瘤的定位和分类；⑥纯化微生物和寄生虫抗原；⑦免疫治疗和与药物结合的免疫-化学疗法 (“导弹”疗法,利用单克隆抗体与靶细胞特异性结合，将药物带至病灶部位.。
因此，单克隆抗体可直接用于人类疾病的诊断、预防、治疗以及免疫机制的研究，为人类恶性肿瘤的免疫诊断与免疫治疗开辟了广阔前景。
